John G Ullman & Associates Inc. Sells 6,675 Shares of Amgen Inc. $AMGN

Posted by George Bondi on Jul 18th, 2026

John G Ullman & Associates Inc. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 75.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,125 shares of the medical research company’s stock after selling 6,675 shares during the period. John G Ullman & Associates Inc.’s holdings in Amgen were worth $748,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Cornerstone Planning Group LLC grew its position in shares of Amgen by 26.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 221 shares of the medical research company’s stock valued at $73,000 after buying an additional 46 shares during the last quarter. Townsend Asset Management Corp NC ADV boosted its holdings in shares of Amgen by 1.4% during the 1st quarter. Townsend Asset Management Corp NC ADV now owns 4,593 shares of the medical research company’s stock worth $1,616,000 after buying an additional 63 shares in the last quarter. Advisortrust Partners LLC grew its holdings in Amgen by 7.7% in the first quarter. Advisortrust Partners LLC now owns 12,001 shares of the medical research company’s stock worth $4,223,000 after purchasing an additional 862 shares during the period. Assetmark Inc. grew its stake in shares of Amgen by 6.9% in the 1st quarter. Assetmark Inc. now owns 243,853 shares of the medical research company’s stock valued at $85,800,000 after buying an additional 15,719 shares during the period. Finally, Main Street Group LTD acquired a new stake in Amgen in the first quarter valued at approximately $59,000. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group initiated coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. Morgan Stanley decreased their target price on Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 8th. Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Guggenheim boosted their price objective on Amgen from $340.00 to $343.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Finally, BMO Capital Markets restated an “outperform” rating and set a $400.00 target price on shares of Amgen in a research report on Wednesday, July 1st. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $356.62.

View Our Latest Report on AMGN

Amgen Trading Down 1.4%

Shares of AMGN stock opened at $366.29 on Friday. The company has a market capitalization of $197.69 billion, a PE ratio of 25.49, a price-to-earnings-growth ratio of 3.76 and a beta of 0.41. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The business’s fifty day moving average is $347.69 and its 200 day moving average is $350.38. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen advanced its obesity pipeline with fresh Phase 1 data on AMG 133 injection formats, which could support long-term growth if the program continues to show promise. Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
Positive Sentiment: Amgen’s stock was highlighted in market coverage as teasing a buy point, suggesting technical traders may see room for upside if broader market conditions stabilize. Stock Market Today: Dow Sees Red While Amgen Shares Tease A Buy Point (Live Coverage)
Neutral Sentiment: Amgen remains a candidate for another earnings beat, according to recent coverage pointing to its history of topping estimates and solid fundamentals. Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Amgen to $23.58 from $23.62 and kept a Hold rating, a modest negative for sentiment but not a major change in the outlook. Amgen Inc. (NASDAQ:AMGN) Free Report
Negative Sentiment: Amgen halted a late-stage bemarituzumab gastric cancer trial, adding uncertainty to part of its oncology pipeline and pressuring investor expectations. Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
Negative Sentiment: Amgen also terminated a key Phase 3 rocatinlimab eczema study, another setback that may raise concerns about the durability of its pipeline growth. Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Amgen Company Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.